Stone Pharmaceutical Group (01093): The Phase Ib/II clinical trial of SYS 6090 injection for the treatment of colorectal cancer has officially commenced at the first research center in China.

The Zhitong Finance APP reported that Shiyao Group (01093) announced that the Phase Ib/II clinical trial (SYS 6090-008) for the combined treatment regimen of SYS 6090 injection for colorectal cancer has officially started at the first research center in China.